• Home
  • Study Details
Not currently enrolling

NEFECON for IgA Nephropathy

"This study is for patients diagnosed with Primary IgA Nephropathy, a kidney disease . it involves research and is conducted to determine the efficacy and safety of a drug called Nefecon (with the active ingredient, budesonide) The purpose of the study is to look at: • How well Nefecon works for the treatment of kidney disease and more specific for patients with the disease ""primary immunoglobulin A nephropathy"", called IgAN; and • How safe and effective Nefecon is compared to placebo."

Age & Gender

  • 18 years ~ 99 years
  • Male, Female

Contact the Team


Thank you for your interest, but this study is not currently enrolling.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Amy Mottl

Study Topics

Kidneys and Liver

IRB Number


logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research
Research for Me logo

Copyright © 2013-2020 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.


  • This email address is being protected from spambots. You need JavaScript enabled to view it.